A Clinical Trial To Determine The Optimal Timing Of Androgen Deprivation In Relapsed Or Non-curable Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$627,600.00
Summary
The aim of the study is to clarify when is the optimal time to start hormone treatment for men with certain stages of prostate cancer. It has long been known that testosterone removal impedes prostate cancer growth, although not permanently. The removal of testosterone, however, has side effects , including loss of libido, hot flushes, weight gain, and in the longer term osteoporosis, loss of muscle bulk and mental changes such as loss of memory. Any benefit to be gained for a patient must there ....The aim of the study is to clarify when is the optimal time to start hormone treatment for men with certain stages of prostate cancer. It has long been known that testosterone removal impedes prostate cancer growth, although not permanently. The removal of testosterone, however, has side effects , including loss of libido, hot flushes, weight gain, and in the longer term osteoporosis, loss of muscle bulk and mental changes such as loss of memory. Any benefit to be gained for a patient must therefore be weighed against these side effects. This is particularly relevant in situations in which cure is not possible, when the aim of treatment should be to manage symptoms (either by preventing or delaying them or treating them as they arise). There are two situations in which a man may be diagnosed as having active prostate cancer but be without symptoms requiring immediate treatment. The first is after the failure of curative treatment, shown by the presence of prostate specific antigen (PSA) in the blood, but without any other evidence of prostate cancer. The second is a man newly diagnosed with asymptomatic prostate cancer, but with other reasons (such as heart disease) which make an attempt at cure inappropriate. We do not know in either case whether or not men live longer if treatment is started immediately, or whether it is reasonable to wait until symptoms develop, thus potentially postponing the side effects of treatment. The trial will therefore include these two groups of men. Half the men will be randomised to receive immediate treatment, and half to treatment starting when symptoms develop, or when there is evidence of progressive disease. The main endpoint is overall survival, balanced against quality of life and side effects from the disease and treatment. The hypothesis is that early treatment will improve survival with acceptable effects on quality of life.Read moreRead less
Modelling The Impact Of Strategies To Control Gonorrhoea And Minimise The Threat Of Antimicrobial Resistance In Remote Indigenous And Other High Risk Populations
Funder
National Health and Medical Research Council
Funding Amount
$467,079.00
Summary
Gonorrhoea is a serious public health issue in Australia. Notification rates are disproportionately high among Aboriginal and Torres Strait Islander people and men who have sex with men, and there is evidence of an emerging epidemic in the general heterosexual population. Additionally, available treatments are under threat from resistant strains. We will use mathematical modelling to evaluate strategies for controlling gonorrhoea and for minimising the threat of antimicrobial resistance.
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
Sexually Transmissible Infections: Outcomes And Interventions.
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Professor Basil Donovan, Head of the Sexual Health Program at UNSW's Kirby Institute, works on a wide range of research endeavours that are aimed at (a) better characterising the causes of sexually transmissible infections (STIs) and their outcomes, (b) determining how they move through populations, and (c) trialing interventions to bring them under control. He has a particular interest in populations that are at increased risk of STIs such as Aboriginal and Torres Strait Islander people, gay me ....Professor Basil Donovan, Head of the Sexual Health Program at UNSW's Kirby Institute, works on a wide range of research endeavours that are aimed at (a) better characterising the causes of sexually transmissible infections (STIs) and their outcomes, (b) determining how they move through populations, and (c) trialing interventions to bring them under control. He has a particular interest in populations that are at increased risk of STIs such as Aboriginal and Torres Strait Islander people, gay men, sex workers, prisoners, and youth.Read moreRead less